How ESG works

A suturing device is passed through the mouth. Working from inside the stomach, it places full-thickness sutures that fold the stomach wall in on itself and narrow the stomach into a tube. Nothing is cut out, and nothing is implanted.

That delay is the mechanism, and it is not the one most people assume. The intuitive account is that making the stomach smaller turns down the hunger hormone produced there. Measured directly, fasting ghrelin was higher eighteen months afterward, and a separate study found no change at all.C-IV-05 ESG works through capacity and timing, which is also how the FDA's own device classification describes it; it is not a ghrelin-lowering operation.

A therapy that does target ghrelin directly exists, and it is a different one: gastric mucosal ablation, which remains investigational.C-IV-06 Everself does not offer it.

The pooled figure comes from a meta-analysis of 1,772 patients that Dr. Thompson co-authored. Three points about how that number is presented elsewhere deserve attention.

Importantly, these figures are total body weight loss, not excess weight loss. ESG is often described in terms of excess weight loss instead, which expresses the same result against a different denominator and makes it sound roughly three times larger.C-IV-02

The pivotal trial was open-label with no sham arm, industry-funded, and reported 13.6%.C-IV-02 The only sham-controlled trial found a smaller effect, in 40 patients with MASH liver disease followed over 72 weeks, with weight as a secondary outcome: 9.47% against 3.91%, with wide variation.C-IV-03 That gap suggests that some of the larger figure reflects knowing one has had the procedure, and the population studied is not the general one.

Pooled severe adverse events run at about 2.2%C-IV-12 and most commonly take the form of pain or nausea requiring hospitalization (1.1%), upper gastrointestinal bleeding (0.6%), and peri-gastric leak or fluid collection (0.5%).

These events are uncommon, but they are not trivial, and they should be weighed accordingly.

ESG received FDA De Novo authorization on 12 July 2022, for people with a BMI between 30 and 50.C-IV-01 De Novo authorization is a specific pathway for devices that have no existing equivalent, which is what it means to be first, and it is not the same as the approval process a drug goes through.